General contact information for trials in British Columbia:
- http://www.bccancer.bc.ca/our-research/participate/clinical-trials/open-clinical-trials
- https://www.clinicaltrialsbc.ca/ (236-521-2064, info@clinicaltrialsbc.ca)
Currently NOT recruiting:
ID Number: NCT03797326
Links:
Description:This study is looking at the safety and effectiveness of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/Mk-7902).
Group A: Pembrolizumab and lenvatinib
Intervention: Pembrolizumab is an immunotherapy drug that will help immune system cells to attack and get rid of cancer cells. Lenvatinib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.
Can I consider participating?